Patent law shift tilts scales toward inventors, away from competition
S. 708 — RESTORE Patent Rights Act of 2025 · Filed by Christopher Coons (D-DE) · 1 cosponsor · Introduced Feb 25, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends patent law to create a legal presumption that courts should grant permanent injunctions (court orders stopping infringement) when a patent owner wins an infringement case, unless the defendant can rebut that presumption with equitable defenses. The bill reverses a recent shift in judicial practice and aims to restore what Congress characterizes as the historical default: that winning a patent case entitles the owner to an injunction stopping the infringing conduct, rather than leaving it to the court's discretion.
Why we flagged it
The bill's core mechanism is a procedural change to patent infringement remedies—shifting the burden of proof in injunction decisions. It is not a substantive patent-rights expansion but a litigation-process reform that favors patent holders in court proceedings.
What the text implies
- Injunctions can block entire product lines, not just infringing components, giving patent holders leverage to extract high licensing fees or settlements from larger companies that cannot afford to redesign products.
- The presumption may disproportionately benefit patent-holding entities (including non-practicing entities / 'patent trolls') that do not manufacture products themselves but hold patents primarily to litigate, as they face no countervailing injunction risk.
- Consumers and downstream businesses may face higher prices or reduced product availability if injunctions prevent competitors from offering alternatives, even if those alternatives could be designed around the patent with modest engineering changes.
- The bill does not define what constitutes a sufficient 'equitable defense' to rebut the presumption, leaving courts to develop standards—creating uncertainty and potentially inconsistent outcomes across jurisdictions.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill benefits individual inventors, startups, and small patent holders by making it easier to stop large companies from copying their inventions, which could encourage innovation and protect smaller players. However, it may increase costs for consumers and businesses that rely on patented technologies, as injunctions can block cheaper alternatives and reduce competitive pressure on patent holders to license their inventions at reasonable rates.
Who stands to gain
- individual inventors and patent holders
- small and medium-sized enterprises holding patents
- universities and research institutions with patent portfolios
- patent licensing firms and non-practicing entities (NPEs)
- patent litigation law firms
Named in the bill
U.S. Congress, U.S. Courts, Patent owners, Large multinational companies, Individual inventors, Institutions of higher education, Startups, Small and medium-sized enterprises, Title 35, United States Code, Section 283
Where it stands
1 cosponsor: 1 Republicans.
- Feb 25, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Feb 25, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
21 lobbying clients named this bill on 30 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $28,146,909 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 97% of bills with at least one filing.
Christopher Coons, the sponsor, reported $1,402,800 in PAC receipts in the 2026 cycle. $6,000 of that came from 2 PACs tied to these lobbying clients.
- Pharmaceutical Research and Manufacturers of America — $8,410,000 on 1 filing
- Amazon.com Services LLC — $4,360,000 on 1 filing
- Dell Technologies Inc — $2,970,000 on 2 filings
- Apple Inc — $2,740,000 on 1 filing
- Amgen Inc — $2,440,000 on 1 filing
Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (2,668 characters) on Aug 13, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 21, 2026 · page rendered 2026-10-20.
- S. 708 on Congress.gov
- Actions and status history
- Cosponsors (1)
- Bill text the analysis read
- Pharmaceutical Research and Manufacturers of America — LDA filing, 2025 Q4
- Amazon.com Services LLC — LDA filing, 2026 Q2
- Dell Technologies Inc — LDA filing, 2026 Q2
- Christopher Coons — FEC candidate receipts, 2026 cycle
“Patent law shift tilts scales toward inventors, away from competition” QuorumCivic. https://share.quorumcivic.app/bill/119/s708 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.